76th Annual Meeting of the AUA Mid-Atlantic Section: APP Program (2018)

October 6, 2018

76th Annual meeting of the Mid-Atlantic Section of the American Urological Association.

 

    Target Audience

    • Urologist
    • Resident
    • Advanced Practice Provider
    • Non-Urologist (MD or DO)
    • Researcher
    • Medical Student
    • Practice Manager

     

    Learning Objectives

    After partcipating in this activity, participants will be able to:

    1. Discuss emerging trends, clinical trials and outcomes for bladder cancer and testicular cancer.
    2. Discuss emerging trends and strategies for physician office practices and workflow.
    3. Discuss emerging trends, clinical trials and outcomes for adult urology, endourology and infertility.
    4. Describe the impact of finasteride on risk of prostate cancer, risk of prostate cancer death, detection of prostate cancer, and side effects of the medication.
    5. Analyze the current health care model in the U.S., recognize the role of physician leadership.
    6. Discuss emerging trends, clinical trials and outcomes for prostate cancer and kidney cancer
    7. Discuss emerging trends, clinical trials and outcomes for female urology, pelvic health, men’s health, trauma and reconstruction.
    8. Identify best practices including how to meet essential requirements relating to the Medicare Access and CHIP Reauthorization Act (MACRA) and the Merit Based Incentive Payments System (MIPS).
    9. Review newly released AUA Guidelines on the topics of:  Surgical Management of BPH, Testosterone Deficiency and Erectile Dysfunction and Castrate Resistant Prostate Cancer.
    10. Recognize current best practices and tips in how to navigate urology coding challenges.
    11. Give examples of how to integrate and sustain a research program both in academic and private practice.
    12. Recognize the impact of mergers and acquisitions and the impact on urology practices.
    13. Describe the importance of patient navigation in BPH, OAB and Cancer with respect to patient treatment outcomes.
    14. Give examples of how to integrate advanced practice providers in various current urology practices.
    15. Describe the current treatment guidelines for testosterone therapy.
    16. Describe novel prostate cancer imaging techniques.
    17. Identify the APP's role in treating patients in the areas of Voiding Dysfunction with Urodynamics, Oncology, OAB, Stones and PSA.
    18. Discuss the quality of life and care issues that surround patients with cancer as they transition into life after treatment.
    19. Identify transdisciplinary approaches to develop innovative, integrated care plans to address common pelvic floor problems.
    Course summary
    Available credit: 
    • 5.25 AMA PRA Category 1 Credit™
    • 5.25 Non-Physician Participation
    Course opens: 
    10/06/2018
    Course expires: 
    10/06/2021
    Event starts: 
    10/06/2018 - 6:00am EDT
    Event ends: 
    10/06/2018 - 11:45pm EDT
    Rating: 
    0
    Washington, DC
    United States

    Accreditation: This activity has been planned and implmented in accordance with the accreidtation requirements and polices of the Accrediation Council for Continuing Medical Education  (ACCME)  through the joint providership of the American Urological Association (AUA) and the Mid-Atalntic Section of the AUA.  The AUA is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation: The American Urological Association designates this live activity for a maximum of 20.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.

    Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

    AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

    Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

    • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Work Group or its subgroup.
    • Limit content to evidence with no recommendations
    • Introduction of a debate format with an unbiased moderator (point-counterpoint)
    • Inclusion of moderated panel discussion
    • Publication of a parallel or rebuttal article for an article that is felt to be biased
    • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
    • Divestiture of the relationship by faculty

    Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


    AUA PARTICIPANT INFORMATION & POLICIES

    Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

    Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

    Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

    Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

    Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

    Available Credit

    • 5.25 AMA PRA Category 1 Credit™
    • 5.25 Non-Physician Participation
    Please login or register to take this course.

    This activity is restricted to attendees of the Mid-Atlantic Section Annual Meeting, Saturday APP Program.